Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

San Miguel, Jesus; Weisel, Katja; Moreau, Philippe; Lacy, Martha; Song, Kevin; Delforge, Michel; Karlin, Lionel; Goldschmidt, Hartmut; Banos, Anne; Oriol, Albert; Alegre, Adrian; Chen, Christine; Cavo, Michele; Garderet, Laurent; Ivanova, Valentina; Martinez-Lopez, Joaquin; Belch, Andrew; Palumbo, Antonio; Schey, Stephen; Sonneveld, Pieter; Yu, Xin; Sternas, Lars; Jacques, Christian; Zaki, Mohamed; Dimopoulos, Meletios

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

Autor(en):

San Miguel, Jesus; Weisel, Katja; Moreau, Philippe; Lacy, Martha; Song, Kevin; Delforge, Michel; Karlin, Lionel; Goldschmidt, Hartmut; Banos, Anne; Oriol, Albert; Alegre, Adrian; Chen, Christine; Cavo, Michele; Garderet, Laurent; Ivanova, Valentina; Martinez-Lopez, Joaquin; Belch, Andrew; Palumbo, Antonio; Schey, Stephen; Sonneveld, Pieter; Yu, Xin; Sternas, Lars; Jacques, Christian; Zaki, Mohamed; Dimopoulos, Meletios

Tübinger Autor(en):

Weisel, Katja

Erschienen in:

Lancet Oncology (2013), Bd. 14, H. 11, S. 1055-1066

Verlagsangabe:

Elsevier Science Inc

Sprache:

Englisch

Referenz zum Volltext:

http://dx.doi.org/10.1016/S1470-2045(13)70380-2

ISSN:

1470-2045